Modular analysis of peripheral blood gene expression in rheumatoid arthritis captures reproducible gene expression changes in tumor necrosis factor responders

Arthritis and Rheumatology

Volumn 67, Issue 2, 2015, Pages 344-351

  Oswald, Michaela ^a   Curran, Mark E ^b   Lamberth, Sarah L ^b   Townsend, Robert M ^c   Hamilton, Jennifer D ^d   Chernoff, David N ^e   Carulli, John ^f   Townsend, Michael J ^g   Weinblatt, Michael E ^h   Kern, Marlena ^a   Pond, Cassandra M ^a   Lee, Annette ^a   Gregersen, Peter K ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c BRISTOL MYERS SQUIBB   (United States)

^d REGENERON PHARMACEUTICALS INC   (United States)

^e Silvestrum Climate Associates   (United States)

^f BIOGEN   (United States)

^g GENENTECH INC   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; RIBOSOME PROTEIN; TUMOR NECROSIS FACTOR; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; RNA; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; COHORT ANALYSIS; DOWN REGULATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GENE PROBE; GENETIC TRANSCRIPTION; HUMAN; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEPTOR BLOCKING; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; RNA; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922821199     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38947     Document Type: Article

References (23)

1. Feldmann M, Maini RN,. Anti-TNFα therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19: 163-96.
2. Scott DL, Wolfe F, Huizinga TW,. Rheumatoid arthritis. Lancet 2010; 376: 1094-108.
3. Kay J, Morgacheva O, Messing SP, Kremer JM, Greenberg JD, Reed GW, et al. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther 2014; 16: R40.
4. Centola M, Cavet G, Shen Y, Ramanujan S, Knowlton N, Swan KA, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One 2013; 8: e60635.
5. Ringold S, Lu L, Wallace CA, Sasso EH, Eastman PS,. A7: initial assessment of multi-biomarker disease activity assay in JIA [abstract]. Arthritis Rheumatol 2014; 66 Suppl S3: S10-11.
6. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.
7. Toonen EJ, Gilissen C, Franke B, Kievit W, Eijsbouts AM, den Broeder AA, et al. Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis. PLoS One 2012; 7: e33199.
8. Van Baarsen LG, Wijbrandts CA, Gerlag DM, Rustenburg F, van der Pouw Kraan TC, Dijkmans BA, et al. Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis. Genes Immun 2010; 11: 622-9.
9. Oliveira RD, Fontana V, Junta CM, Marques MM, Macedo C, Rassi DM, et al. Differential gene expression profiles may differentiate responder and nonresponder patients with rheumatoid arthritis for methotrexate (MTX) monotherapy and MTX plus tumor necrosis factor inhibitor combined therapy. J Rheumatol 2012; 39: 1524-32.
10. Julia A, Erra A, Palacio C, Tomas C, Sans X, Barcelo P, et al. An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis. PLoS One 2009; 4: e7556.
11. Bienkowska JR, Dalgin GS, Batliwalla F, Allaire N, Roubenoff R, Gregersen PK, et al. Convergent Random Forest predictor: methodology for predicting drug response from genome-scale data applied to anti-TNF response. Genomics 2009; 94: 423-32.
12. Koczan D, Drynda S, Hecker M, Drynda A, Guthke R, Kekow J, et al. Molecular discrimination of responders and nonresponders to anti-TNFα therapy in rheumatoid arthritis by etanercept. Arthritis Res Ther 2008; 10: R50.
13. Lequerre T, Gauthier-Jauneau AC, Bansard C, Derambure C, Hiron M, Vittecoq O, et al. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther 2006; 8: R105.
14. Mesko B, Poliska S, Vancsa A, Szekanecz Z, Palatka K, Hollo Z, et al. Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease. Genome Med 2013; 5: 59.
15. Meugnier E, Coury F, Tebib J, Ferraro-Peyret C, Rome S, Bienvenu J, et al. Gene expression profiling in peripheral blood cells of patients with rheumatoid arthritis in response to anti-TNF-α treatments. Physiol Genomics 2011; 43: 365-71.
16. Smith SL, Plant D, Eyre S, Barton A,. The potential use of expression profiling: implications for predicting treatment response in rheumatoid arthritis. Ann Rheum Dis 2013; 72: 1118-24.
17. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, Baldwin N, et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 2008; 29: 150-64.
18. Gregersen PK, Oswald M,. The power of a modular approach to transcriptional analysis [editorial]. Arthritis Rheumatol; 2014 66: 1418-20.
19. Weinblatt ME, Bingham CO III, Mendelsohn AM, Kim L, Mack M, Lu J, et al. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis 2013; 72: 381-9.
20. Du P, Kibbe WA, Lin SM,. Lumi: a pipeline for processing Illumina microarray. Bioinformatics 2008; 24: 1547-8.
21. Smyth GK,. Limma: linear models for microarray data. In:, Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, editors. Bioinformatics and computational biology solutions using R and Bioconductor. New York: Springer; 2005. p. 397-420.
22. Curtis JR, van der Helm-van Mil AH, Knevel R, Huizinga TW, Haney DJ, Shen Y, et al. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken) 2012; 64: 1794-803.
23. Topol EJ,. Individualized medicine from prewomb to tomb. Cell 2014; 157: 241-53.